Stanford scientists have developed a high throughput screening method to identify therapeutics known as translational activators to treat protein synthesis disorders and ribosomopathies.
Stanford researchers in Prof. Corinne Beinat's lab have developed a small molecule radiotheranostic for targeted radionuclide therapy of cancers overexpressing system xc-, such as high-grade glioma and non-small cell lung cancer (NSCLC).
Stanford researchers have developed ModulADAR - a novel RNA sensing platform that enables precise, cell-type or state-specific activation of mRNA expression using ADAR editing, offering unparalleled flexibility and specificity for targeted RNA therapeutics.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Researchers at Stanford have developed a computational tool that enables the discovery of regenerative cells across all tissue types and novel targets in cancer.
Researchers at Stanford have developed fusion proteins, containing ACE2 domain linked to a fragment of non-neutralizing anti-SARS-CoV-2 spike protein antibody, with a greater breadth of protection than previously described similar fusion proteins.
Stanford scientists have discovered that the untranslated region (UTR) of RNA can be engineered into autonomous switches capable of both sensing native biological conditions (e.g.
Stanford researchers have engineered hematopoietic stem cells to provide long-term secretion of chosen therapeutic antibodies, eliminating the need of repeated dosing for delivery.
Researchers in Dr. Michelle Monje-Deisseroth's lab at Stanford have identified therapeutic targets for drug development to limit the spread of high-grade gliomas (HGGs).
Stanford scientists have developed PVSeg, a tool that automatically segments vascular and perivascular compartments in brain MRI data. This innovative tool can identify non-demented individuals at increased risk of developing dementia and accelerated brain atrophy.
Of the 1.4 million first time mothers giving vaginal birth in the United States, approximately 75% will experience tearing of their vagina or perineum.